Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar

Dr. Reddy's Laboratories (RDY) announced entering into a license and supply agreement with Iceland-based partner, Alvotech (ALVO) , for the commercialization of AVT03. AVT03, a human monoclonal antibody, is Alvotech's biosimilar candidate to Amgen's Prolia and Xgeva (denosumab). Both Prolia and Xgeva are currently approved to treat various indications, including osteoporosis in postmenopausal women and prevention of skeletal-related events in adults with advanced malignancies. The collaboration agreement se ...